Speaker illustration

Doctor Samuele Ambrosini

University of Zurich, Schlieren (Switzerland)

The histone methyltransferase SETD2 drives cardiometabolic heart failure with preserved ejection fraction

Event: ESC Congress 2022

Topic: Heart Failure

Session: Pathomechanisms of heart failure with preserved ejection fraction

Thumbnail

A methylation-dependent checkpoint by SETD7 promotes myocardial ischemic injury in mice and men

Event: ESC Congress 2022

Topic: Ischaemia, Infarction, Cardioprotection

Session: Ischaemia-mediated cardiac injury: pathomechanisms and potential treatments

Thumbnail

Targeting the methyltransferase setd7 prevents myocardial ischemic injury: a translational study

Event: ESC Congress 2021 - The Digital Experience

Topic: Ischaemia, Infarction, Cardioprotection

Session: Highlights from the Young in basic science

Thumbnail

Methylation of the hippo signalling effector YAP by SETD7 drives myocardial ischemic injury

Event: ESC CONGRESS 2020 - The Digital Experience

Topic: Ischaemia, Infarction, Cardioprotection

Session: Young Investigator Award Session Basic Science

Thumbnail

The methyltransferase SETD7 promotes myocardial ischemic injury by activating Hippo signalling

Event: ESC CONGRESS 2019

Topic: Ischaemia, Infarction, Cardioprotection

Session: Cardiac repair and signalling

Thumbnail

ESC 365 is supported by

logo Novo Nordisk